Detalles de la búsqueda
1.
Assessing the use of anti-PD1 monotherapy as adjuvant therapy and determinants of treatment choice in stage III cutaneous melanoma in the US.
BMC Cancer
; 24(1): 389, 2024 Mar 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38539148
2.
Time and productivity loss associated with immunotherapy infusions for the treatment of melanoma in the United States: a survey of health care professionals and patients.
BMC Health Serv Res
; 23(1): 136, 2023 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36759810
3.
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Lancet Oncol
; 19(9): 1192-1204, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30100375
4.
Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.
Invest New Drugs
; 32(2): 303-11, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23903897
5.
Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
J Clin Oncol
; 41(24): 3998-4003, 2023 08 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37348035
6.
Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
NEJM Evid
; 1(11): EVIDoa2200214, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-38319852
7.
Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
Clin Cancer Res
; 22(2): 301-9, 2016 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26324738
8.
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.
Clin Cancer Res
; 22(21): 5204-5210, 2016 Nov 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27797971
Resultados
1 -
8
de 8
1
Próxima >
>>